Division of Plastic Surgery, Mayo Clinic, Jacksonville, FL, U.S.A.
Department of Surgery, Mayo Clinic, Jacksonville, FL, U.S.A.
Anticancer Res. 2019 Nov;39(11):6333-6337. doi: 10.21873/anticanres.13844.
BACKGROUND/AIM: To characterize the demographics, tumor staging and treatment of African American (AA) patients diagnosed with melanoma in the United States.
The National Cancer Database was used to extrapolate data from patients with melanoma between January 1, 2004, and December 31, 2015. The patients were then further divided based on ethnicity (AAs vs. Caucasians) to compare patient efficacy of treatment.
The mean time for AA patients to receive treatment was 20.37 days compared with 11.25 days for Caucasians (p<0.001), while time to surgery was 38.86 days compared to 31.12 days for Caucasians (p<0.001). Moreover, AA race was a predictor of American Joint Committee on Cancer stage greater than II, tumor diagnosed at autopsy, presence of ulceration, and distribution in the extremities.
AA patients with melanoma are more likely to have worse tumor staging, treatment delay, treatment at an Integrated Cancer Program, and diagnosis at autopsy.
背景/目的：描述在美国被诊断为黑色素瘤的非裔美国人（AA）患者的人口统计学、肿瘤分期和治疗情况。
从 2004 年 1 月 1 日至 2015 年 12 月 31 日，国家癌症数据库被用来推断黑色素瘤患者的数据。然后，根据种族（AA 与白人）将患者进一步分组，以比较治疗的患者疗效。
AA 患者接受治疗的平均时间为 20.37 天，而白人患者为 11.25 天（p<0.001），而手术时间为 38.86 天，而白人患者为 31.12 天（p<0.001）。此外，AA 种族是美国癌症联合委员会分期大于 II 期、尸检诊断、溃疡存在和四肢分布的预测因素。
患有黑色素瘤的 AA 患者更有可能出现更差的肿瘤分期、治疗延迟、在综合癌症计划中接受治疗以及尸检诊断。
